ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome



Status:Archived
Conditions:Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome


This is a dose-escalation study to determine the maximum tolerated dose (MTD) of ARRY-614 in
patients with Myelodysplastic Syndrome (MDS).



We found this trial at
3
sites
H. Lee Moffitt Cancer Center & Research Institute
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
M. D. Anderson Cancer Center
1400 South Orange Avenue
Orlando, Florida 32806
407-648-3800
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Winship Cancer Institute of Emory University
Egleston, Georgia 30322
?
mi
from
Egleston, GA
Click here to add this to my saved trials